Contribute Try STAT+ Today

Moderna’s work on a vaccine for coronavirus has made its founders into paper billionaires. Gilead Sciences has added $10 billion to its market value since the start of 2020. And a rising tide of Covid-19 speculation has sent one major biotech index to its all-time high.

But Sinovac, a Beijing-headquartered company with a coronavirus vaccine already in human trials, has been entirely left out. Thanks to a yearslong battle for corporate control — involving a secret coup, a poison pill, and an office raid — trading of Sinovac’s shares has been halted since early 2019, making for Nasdaq’s longest ongoing suspension.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Comments are closed.